QGEN vs. RGEN, NBIX, TECH, EXEL, CRSP, PCVX, HALO, DNLI, ABCM, and DNA
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Abcam (ABCM), and Ginkgo Bioworks (DNA). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen vs.
Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Repligen has a net margin of 21.58% compared to Qiagen's net margin of 17.66%. Qiagen's return on equity of 14.08% beat Repligen's return on equity.
58.6% of Qiagen shares are owned by institutional investors. Comparatively, 91.0% of Repligen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 1.1% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Qiagen and Qiagen both had 4 articles in the media. Repligen's average media sentiment score of 0.80 beat Qiagen's score of 0.24 indicating that Repligen is being referred to more favorably in the news media.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen received 154 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.07% of users gave Repligen an outperform vote while only 60.78% of users gave Qiagen an outperform vote.
Qiagen presently has a consensus target price of $54.87, indicating a potential upside of 21.49%. Repligen has a consensus target price of $208.56, indicating a potential upside of 24.20%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Qiagen.
Qiagen has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.
Summary
Repligen beats Qiagen on 12 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools